Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-alpha-glycerophosphorylethanolamine is a small molecule compound with the molecular formula C5H14NO6P and a molecular weight of 215.14 g/mol[1][4][7]. It is also known as ethanolamine glycerophosphate anhydrous. This compound is a metabolite found in or produced by Escherichia coli and has been investigated as an adjunct therapy for the maintenance of cognitive function in the elderly[1][2]. Its mechanism of action is not fully elucidated but it may be involved in phospholipid metabolism due to its structural similarity to phosphatidylethanolamines, which are key components of biological membranes[1][2]. The drug is considered experimental and has not been fully annotated or approved for any indication at this time[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-alpha-glycerophosphorylethanolamine.